Xeris Biopharma (NASDAQ:XERS) Stock: Insider Kevin Mcculloch Sells 15,000 Shares

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider Kevin McCulloch sold 15,000 shares of the stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $10.23, for a total value of $153,450.00. Following the transaction, the insider directly owned 1,584,208 shares of the company’s stock, valued at approximately $16,206,447.84. The trade was a 0.94% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kevin Mcculloch also recently made the following trade(s):

• On Thursday, October 1st, Kevin McCulloch sold 15,000 shares of Xeris Biopharma stock. The shares were sold at an average price of $9.41, for a total value of $141,150.00.
• On Monday, September 28th, Kevin McCulloch sold 25,000 shares of Xeris Biopharma stock. The stock was sold at an average price of $10.00, for a total value of $250,000.00.
• On Tuesday, September 1st, Kevin McCulloch sold 15,000 shares of Xeris Biopharma stock. The stock was sold at an average price of $8.49, for a total value of $127,350.00.

Xeris Biopharma Stock Up 25.0%

Shares of XERS opened at $13.08 on Friday. The stock has a market capitalization of $2.38 billion, a price-to-earnings ratio of -118.91 and a beta of 0.61. Xeris Biopharma Holdings, Inc. has a 1 year low of $5.25 and a 1 year high of $13.74. The business’s 50 day simple moving average is $9.49 and its 200-day simple moving average is $7.58. The company has a debt-to-equity ratio of 17.00, a current ratio of 1.45 and a quick ratio of 1.02.

Xeris Biopharma (NASDAQ:XERS) last posted its earnings results on Thursday, November 5th. The company reported $0.06 EPS for the quarter, beating analysts’ consensus estimates of $0.03 by $0.03. Xeris Biopharma had a positive return on equity of 338.21% and a negative net margin of 5.12%. The firm had revenue of $107.23 million during the quarter, compared to the consensus estimate of $101.68 million. As a group, equities analysts expect that Xeris Biopharma Holdings, Inc. will post 0.07 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. Leerink Partners increased their price objective on shares of Xeris Biopharma from $12.00 to $16.00 and gave the company an “outperform” rating in a research report on Thursday, September 10th. Weiss Ratings cut shares of Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a research note on Tuesday, August 11th. Wall Street Zen upgraded shares of Xeris Biopharma from a “hold” rating to a “buy” rating in a report on Saturday, September 19th. Finally, Barclays boosted their target price on shares of Xeris Biopharma from $12.00 to $14.00 and gave the stock an “overweight” rating in a report on Tuesday, October 6th. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $13.20.

Xeris Biopharma News Summary

Here are the key news stories impacting Xeris Biopharma this week:

• Positive Sentiment: Xeris reported third-quarter earnings of $0.06 per share, beating the $0.03 consensus estimate, while revenue of $107.23 million topped expectations of $101.68 million. The better-than-expected results were a key near-term catalyst. Xeris Biopharma Shares Jump After Q3 Results Top Estimates
• Positive Sentiment: CEO John Shannon reportedly said Recorlev could approach $1 billion in annual sales three to four years earlier than previously expected, strengthening the company’s long-term growth story. Xeris CEO Sees Recorlev Nearing $1B in Annual Sales
• Neutral Sentiment: Several executives reported selling shares at $10.23 under pre-arranged Rule 10b5-1 plans. The reported sales were relatively small compared with their remaining holdings, which tempers the significance of the transactions. Xeris Insider Sale

Institutional Investors Weigh In On Xeris Biopharma

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in XERS. Chicago Partners Investment Group LLC lifted its stake in shares of Xeris Biopharma by 16.3% in the 3rd quarter. Chicago Partners Investment Group LLC now owns 13,286 shares of the company’s stock valued at $136,000 after purchasing an additional 1,861 shares during the last quarter. AlphaCentric Advisors LLC boosted its holdings in shares of Xeris Biopharma by 4.2% in the 3rd quarter. AlphaCentric Advisors LLC now owns 48,489 shares of the company’s stock worth $464,000 after purchasing an additional 1,940 shares during the period. Allworth Financial LP boosted its holdings in shares of Xeris Biopharma by 86.4% in the 2nd quarter. Allworth Financial LP now owns 4,315 shares of the company’s stock worth $34,000 after purchasing an additional 2,000 shares during the period. Jacksonville Wealth Management LLC increased its position in shares of Xeris Biopharma by 11.8% during the 3rd quarter. Jacksonville Wealth Management LLC now owns 19,000 shares of the company’s stock valued at $182,000 after purchasing an additional 2,000 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its position in shares of Xeris Biopharma by 7.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 33,266 shares of the company’s stock valued at $332,000 after purchasing an additional 2,190 shares during the last quarter. 42.75% of the stock is currently owned by hedge funds and other institutional investors.

About Xeris Biopharma

Xeris Biopharma, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for patients with endocrinology, gastroenterology and other serious or chronic conditions. The company uses proprietary formulation and delivery technologies designed to make complex therapies more stable, convenient and suitable for self-administration.

Xeris’ commercial portfolio includes Gvoke, a ready-to-use glucagon injection for the treatment of severe hypoglycemia in adults and children with diabetes; Recorlev (levoketoconazole), an oral therapy for endogenous hypercortisolemia associated with endogenous Cushing’s syndrome; and Keveyis (dichlorphenamide), a treatment for primary periodic paralysis.